Sentences with phrase «submitted program application»
Venue will be confirmed only to candidates with submitted program application 9 am, Singapore, Singapore, Inglés
https://www.ie.edu/ Not exact matches
Our company has taught a lot of people how to code — with more than 1,200 total enrollments selected from over 3,000 applications submitted for our programs.
The application's instructions are clear: In order to be accepted into TechStars, the prestigious accelerator program, start - up founders are asked to submit two videos — one to describe the company's product or service, and the other to introduce the team.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
To be considered for one of these awards, you must be admitted to the program and submit your award application (s) by the designated deadline.
You should read the current application and program guidance before submitting an application to increase your chances of success
The TWQ is an ERC20 token that allows token holders to submit an application to accomplish their personal financing according to the Commodity Tawarruq trading program via an iP2PGlobal platform.
The TWQ (Tawarruq) is an ERC20 token that confer the right to the token holder to submit an application for a personal financing based on a Commodity Tawarruq Trading program, through the iP2PGlobal platform and have it listed in the platform for prospective lenders to view and choose to finance.
Presumably, bishops would be invited to submit applications for funding for their various institutions and programs.
(a) A private or governmental entity seeking accreditation as a certifying agent under this subpart must submit an application for accreditation which contains the applicable information and documents set forth in 205.503 through 205.505 and the fees required in 205.640 to: Program Manager, USDA - AMS - TMP - NOP, Room 2945 — South Building, P.O. Box 96456, Washington, DC 20090 — 6456.
In addition, an updated Let's Move Salad Bars to School site was recently launched to provide a portal for school districts to submit applications to receive a salad bar and for information on how to include a salad bar in their school meal program.
Prior to submitting your application online, companies should fully consider the Legal Terms of the program, as only those companies that accept the terms and conditions are able to proceed to submit an application.
OTA submitted an application to USDA in May 2016 — after over a year of work on behalf of its members through a Transitional task force — to create the transitional certification program, thereby building the foundation for a potential market for transitional products.
For UC San Diego hybrid lactation program pathway 2 application you will be required to identify your health profession, and required to submit a copy of your license, registration, diploma or unofficial transcript.
You can start the application before a Program Advisor is designated, but a PA must be signed up before the application is submitted.
In addition, an updated Let's Move Salad Bars to School site was recently launched to provide a portal for school districts to submit applications to receive a salad bar and for information on how to include a salad bar in their school meal program.
Identified students include those who qualify for free meals because they live in households that participate in the Supplemental Nutrition Assistance Program (SNAP), Temporary Assistance for Needy Families (TANF), or Food Distribution Program on Indian Reservations (FDPIR), as well as children who are certified for free school meals without submitting a school meal application because of their status as being in foster care, enrolled in Head Start, homeless, runaway, or migrant students.
The Broadband Program Office has made Round III RFP guidelines available and will begin accepting applications for broadband funding on the Consolidated Funding Application portal starting on June 6, 2017, and applications must be submitted by August 15, 2017.
Applicants for CDBG funds are required to meet Citizen Participation requirements by issuing a public notice and holding a public hearing prior to submitting an application, and NYMS program applicants must provide a formal resolution in support of the application from the municipality in which the project is located.
The bill submitted by Cuomo as a program measure would prohibit all employers from seeking salary history on an employment application.
One company, Far (m) ed New York LLC, announced it was submitting an application to the state Department of Health to become an official provider of medical marijuana under the state's program, which is due to come online in January.
As the state finalizes the medical marijuana program's draft regulations, advocates are making a final effort to call attention to their concerns over accessibility and affordability before the regulations are approved in the coming weeks and businesses begin submitting applications.
In 2013, applications for 124 films, 33 television programs and 26 pilots were submitted to the state.
Building on his administration's valuable 311 program, he promised to make government more accessible by translating city websites into six languages, distributing more information via Twitter (follow @ 311nyc) and social networking sites, enabling users to fine - tune their usage of NYC.gov around their personal information needs, and creating a free iPhone application allowing people to submit quality - of - life complaints to 311 directly from their phone.
The other two are already being tested: an independent investigator grant program that does not require applicants to submit preliminary data and a process to speed up the resubmission of R01 grant applications by new investigators who fail on their first attempt.
One other thing you need to consider when preparing NIH applications: You can submit an application in response to a specific program announcement (PA) or request for applications (RFA)... or you can choose not to.
NIH has an active pilot program, the NIH electronic research administration (ERA) initiative, in which it will soon encourages applicants to submit certain types of applications — renewals and training grant applications — online.
NSF has taken steps to encourage and enable the use of Grants.gov; in the past 2 years, NSF has reserved a few programs for applications using Grants.gov alone and written a comprehensive 62 - page manual for submitting grant applications through Grants.gov.
Every 3 years, the programs submit internal training grant applications and a committee reviews the program.
Most people in your position would submit an application to NSF's Instructional Materials Development (IMD) program.
-- The Secretary shall evaluate and prioritize an application submitted by a State for a grant under the Program on the basis of --
To apply directly to a PhD program, students should submit an application to the Physics and Astronomy Department at the University of Waterloo.
Eligibility Criteria for application: applicants must be associated with any of the six RICE - CRP centers (mentioned above), conduct their research as part of the RICE program, have submitted an abstract for presentation at the IRC2018 with the applicant as presenter (can be oral presentation, flash talk, or poster).
Applications can be submitted directly though the AAPM Medical Physics Residency Application Program (aapm.org/mprap).
Applications for our Medical Oncology / Hematology Fellowship Program should be submitted through the Electronic Residency Application System (ERAS).
Rolling admissions will begin in March, for applicants who meet program requirements, submit completed application materials, and pay tuition deposit.
Interested candidates are encouraged to send their CV to the Program Coordinator Kerry Wallace prior to submitting the ERAS application.
If you designate your primary field as «Chemistry - Chemistry of Life Processes», for example, you must submit your application on the Chemistry deadline, even if your graduate program is in a Life Sciences department.
For example, panelists evaluating applications submitted to the Graduate Research Fellowship Program may consider the following with respect to the Intellectual Merit Criterion: the potential of the applicant to advance knowledge based on a holistic analysis of the complete application, including the Personal, Relevant Background, and Future Goals Statement, Graduate Research Plan Statement, strength of the academic record, description of previous research experience or publication / presentations, and references.
Analyses were conducted for all applications combined as well as separately for R01 applications (grant applications submitted by individual investigators), other R applications (academic research enhancement awards, exploratory / development grants, small grant program, small business awards), and applications in the K (clinical research training awards for junior and midcareer faculty), P (program projects and center grants), and F (predoctoral and postdoctoral fellowships) series.
«NINDS created this pilot program to improve the value of the research it funds by enabling proven investigators to pursue long - range, innovative research instead of continually writing and submitting grant applications,» said Walter Koroshetz, M.D., the NINDS director.
The preceptor will then submit an application to the Training Program.
YogaFit has officially submitted our Yoga Therapy Program application for accreditation to the International Association of Yoga Therapy!
Once your application has been approved, you will submit an enrollment agreement and a NON-REFUNDABLE deposit of $ 500.00 to hold your space in this program.
Candidates for this advanced standing should indicate this in their application essay and submit their official record of graduation from the Chef's Training Program to the Office of Graduate Admissions office so that the Academic Director can evaluate eligibility.
* Submit your application HERE or contact Sally Delisle, our Director of Trainings, who will work with you to design a personalized program based on your individual intentions and interests.
Find out about our amazing certification programs by Submitting the Scholarship Application and an EHI Welcome Specialist will contact you to get all your questions answered.
We have submitted an application to IAYT for accreditation of our yoga therapy program, and will be able to provide information on our status after IAYT completes our review.
In addition to standard admission and application requirements, applicants transferring from another naturopathic or professional - degree program must also submit the following.
To apply for this program, please review the full rpogram details and submit an online application.